Quick Answer
Pharma-Bio Serv, Inc. reported Total Revenue of $9.00 million for the year ending 2025.
- Pharma-Bio Serv, Inc. showed a decrease of -5.3% in Total Revenue from 2024 to 2025.
- This data is from Pharma-Bio Serv, Inc.'s annual report (Form 10-K), filed with the SEC on January 29, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $3.92 million | Q3 2017: $3.98 million | Q1 2018: $3.73 million | Q2 2018: $3.77 million | Q3 2018: $4.63 million | Q1 2019: $4.57 million | Q2 2019: $5.15 million | Q3 2019: $4.97 million | Q1 2020: $4.61 million | Q2 2020: $5.65 million | Q3 2020: $6.28 million | Q1 2021: $4.49 million | Q2 2021: $5.04 million | Q3 2021: $4.99 million | Q1 2022: $5.02 million | Q2 2022: $4.97 million | Q3 2022: $4.77 million | Q1 2023: $4.24 million | Q2 2023: $4.56 million | Q3 2023: $4.58 million | Q1 2024: $2.38 million | Q2 2024: $2.38 million | Q3 2024: $2.42 million | Q1 2025: $2.47 million | Q2 2025: $2.42 million | Q3 2025: $1.96 million | Q1 2026: $2.29 million.
- Over the full 9 years of available data (2017 to 2025), Pharma-Bio Serv, Inc.'s Total Revenue has declined by 32.3%.
- Historical annual values: Fiscal year 2025: $9.00 million | Fiscal year 2024: $9.51 million | Fiscal year 2023: $16.98 million | Fiscal year 2022: $19.40 million | Fiscal year 2021: $20.12 million | Fiscal year 2020: $21.56 million | Fiscal year 2019: $19.51 million | Fiscal year 2018: $17.80 million | Fiscal year 2017: $13.30 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: